A proposal by the US Department of Health and Human Services (HHS) would expose the actual costs of drugs covered by Medicaid, and hold manufacturers to account for the am
The UK’s voluntary system of revenue rebates to limit rises in medicines spending is already causing deep upset among branded drug manufacturers as clawbacks rise.
Senior lawmakers in the US across both sides of the political divide have released a list of measures that they are considering to reduce medicine costs for patients and t
As a successor to the 2019 Voluntary Scheme for Branded Medicines Access and Pricing is being negotiated, Leela Barham asks where rebates should go in future - that is, if rebates remain at
